阻断IL-17A可以防止氧化诱导的类似抑郁的效应,并提高IL-6水平在腹膜区域,并减少氧化衍生的物理依赖性在老鼠中
Saadet Inan1, Joseph J Meissler1, Shingo Bessho2
1Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Brain, behavior, and immunity
|January 10, 2024
概括
在临床前研究中,慢性使用氧化会导致类似抑郁的效应和疼痛过敏. 通过抗体阻断介素-17A (IL-17A) 阻止了这些效应,这表明氧化使用障碍的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性氧化使用与抑郁症有关,但其临床前发病因子研究不足.
- 介素-17A (IL-17A) 影响情绪障碍和肠道微生物群,使其成为氧化作用的潜在调解者.
研究的目的:
- 研究慢性氧化对情绪,疼痛,依赖,免疫标志物和肠道微生物群的临床前影响.
- 测试阻断IL-17A是否能减轻氧化诱导的行为和神经免疫变化.
主要方法:
- 在12天内,小鼠接受了慢性氧化或盐水注射.
- 为了评估其治疗潜力,联合使用了介素-17A (IL-17A) 抗体或盐水.
- 进行了行为测试,细胞因子水平分析和肠道微生物组评估.
主要成果:
- 慢性氧化诱导了类似抑郁症的效应,过敏症和身体依赖,增加了腹膜区域 (VTA) 的IL-17A和IL-6.
- 同时服用IL-17A抗体可以预防类似抑郁症的效应和过敏症,减少戒断症状,并使细胞因子水平正常化.
- 氧化没有显著改变肠道微生物组或完整性.
结论:
- IL-17A在氧化诱导的类似抑郁症的行为和神经免疫性改变中起着重要作用.
- IL-17A抗体显示出阻断慢性氧化使用不良影响的治疗潜力.
- 需要对IL-17A抗体进行进一步的研究,以治疗氧化使用障碍.
相关概念视频
Analgesia and Pain Management
625
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
625
Opioid Analgesics: Synthetic and Semisynthetic Opioids
300
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
300
Opioid Receptors: Overview
847
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
847
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K
Antidepressant Drugs: MAOIs and Other Agents
237
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
237
Drug Abuse and Addiction: Pharmacological Phenomena
476
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
476


